Rocket Pharmaceuticals (RCKT) Competitors

$2.96 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.01 +0.05 (+1.69%)

As of 05/22/2026 07:33 PM Eastern

RCKT vs. MAZE, URGN, CMPS, PAHC, and BCAX

Should you buy Rocket Pharmaceuticals stock or one of its competitors? MarketBeat compares Rocket Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rocket Pharmaceuticals include Maze Therapeutics (MAZE), Urogen Pharma (URGN), Compass Pathways (CMPS), Phibro Animal Health (PAHC), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry.

How does Rocket Pharmaceuticals compare to Maze Therapeutics?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Rocket Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market.

Maze Therapeutics' return on equity of -36.62% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%
Maze Therapeutics	N/A	-36.62%	-31.78%

In the previous week, Maze Therapeutics had 17 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 21 mentions for Maze Therapeutics and 4 mentions for Rocket Pharmaceuticals. Maze Therapeutics' average media sentiment score of -0.68 beat Rocket Pharmaceuticals' score of -0.73 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Maze Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Maze Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Maze Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A
Maze Therapeutics	$167.50M	8.52	-$131.12M	-$2.53	N/A

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rocket Pharmaceuticals presently has a consensus target price of $11.54, indicating a potential upside of 289.81%. Maze Therapeutics has a consensus target price of $66.00, indicating a potential upside of 156.01%. Given Rocket Pharmaceuticals' higher probable upside, equities research analysts plainly believe Rocket Pharmaceuticals is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Maze Therapeutics beats Rocket Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Urogen Pharma?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Urogen Pharma has higher revenue and earnings than Rocket Pharmaceuticals. Urogen Pharma is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A
Urogen Pharma	$109.79M	12.82	-$153.49M	-$2.75	N/A

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%
Urogen Pharma	-94.83%	N/A	-62.85%

Rocket Pharmaceuticals currently has a consensus price target of $11.54, suggesting a potential upside of 289.81%. Urogen Pharma has a consensus price target of $36.67, suggesting a potential upside of 26.92%. Given Rocket Pharmaceuticals' higher probable upside, research analysts plainly believe Rocket Pharmaceuticals is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Rocket Pharmaceuticals and 2 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.26 beat Rocket Pharmaceuticals' score of -0.73 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rocket Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

Summary

Rocket Pharmaceuticals beats Urogen Pharma on 9 of the 15 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Compass Pathways has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Compass Pathways is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

Compass Pathways presently has a consensus price target of $20.58, indicating a potential upside of 74.29%. Rocket Pharmaceuticals has a consensus price target of $11.54, indicating a potential upside of 289.81%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

Compass Pathways' return on equity of -31.07% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

In the previous week, Compass Pathways had 9 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 13 mentions for Compass Pathways and 4 mentions for Rocket Pharmaceuticals. Compass Pathways' average media sentiment score of 0.60 beat Rocket Pharmaceuticals' score of -0.73 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Compass Pathways beats Rocket Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Phibro Animal Health?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

In the previous week, Phibro Animal Health had 13 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 17 mentions for Phibro Animal Health and 4 mentions for Rocket Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.68 beat Rocket Pharmaceuticals' score of -0.73 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Phibro Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Rocket Pharmaceuticals presently has a consensus target price of $11.54, indicating a potential upside of 289.81%. Phibro Animal Health has a consensus target price of $38.80, indicating a potential upside of 16.66%. Given Rocket Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Phibro Animal Health	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Phibro Animal Health has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A
Phibro Animal Health	$1.30B	1.04	$48.26M	$2.33	14.27

Rocket Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Phibro Animal Health has a net margin of 6.35% compared to Rocket Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%
Phibro Animal Health	6.35%	37.14%	8.57%

Summary

Phibro Animal Health beats Rocket Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Bicara Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Bicara Therapeutics has a beta of -0.57, indicating that its stock price is 157% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 15.5% of Bicara Therapeutics shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Bicara Therapeutics had 7 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 11 mentions for Bicara Therapeutics and 4 mentions for Rocket Pharmaceuticals. Bicara Therapeutics' average media sentiment score of 0.10 beat Rocket Pharmaceuticals' score of -0.73 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Bicara Therapeutics' return on equity of -35.89% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

Bicara Therapeutics currently has a consensus target price of $30.27, suggesting a potential upside of 39.63%. Rocket Pharmaceuticals has a consensus target price of $11.54, suggesting a potential upside of 289.81%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

Summary

Bicara Therapeutics beats Rocket Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCKT vs. The Competition

Export

Metric	Rocket Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$323.21M	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.58	10.34	17.93	22.89
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	1.36	7.09	10.37	7.14
Net Income	-$223.12M	$24.45M	$3.57B	$335.98M
7 Day Performance	-3.58%	5.45%	6.01%	3.56%
1 Month Performance	-15.91%	2.43%	3.52%	2.54%
1 Year Performance	-52.79%	62.98%	34.13%	35.05%

Rocket Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCKT Rocket Pharmaceuticals	2.2952 of 5 stars	$2.96 flat	$11.54 +289.8%	-52.8%	$323.21M	N/A	N/A	240	Gap Up
MAZE Maze Therapeutics	2.1594 of 5 stars	$24.50 -4.1%	$66.00 +169.4%	+150.8%	$1.41B	$167.50M	N/A	121	Analyst Revision
URGN Urogen Pharma	3.357 of 5 stars	$28.58 -0.7%	$36.67 +28.3%	+589.5%	$1.40B	$109.79M	N/A	200	Gap Up
CMPS Compass Pathways	3.8368 of 5 stars	$10.56 +1.8%	$20.58 +94.9%	+170.9%	$1.40B	N/A	N/A	120	Analyst Forecast
PAHC Phibro Animal Health	4.6794 of 5 stars	$34.18 -0.6%	$38.80 +13.5%	+43.1%	$1.39B	$1.30B	14.67	2,475	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCKT) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. MAZE, URGN, CMPS, PAHC, and BCAX

How does Rocket Pharmaceuticals compare to Maze Therapeutics?

Summary

How does Rocket Pharmaceuticals compare to Urogen Pharma?

Summary

How does Rocket Pharmaceuticals compare to Compass Pathways?

Summary

How does Rocket Pharmaceuticals compare to Phibro Animal Health?

Summary

How does Rocket Pharmaceuticals compare to Bicara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. MAZE, URGN, CMPS, PAHC, and BCAX

How does Rocket Pharmaceuticals compare to Maze Therapeutics?

Which has more risk & volatility, RCKT or MAZE?

Is RCKT or MAZE more profitable?

Does the media prefer RCKT or MAZE?

Which has better valuation and earnings, RCKT or MAZE?

Do insiders and institutionals believe in RCKT or MAZE?

Do analysts prefer RCKT or MAZE?

Summary

How does Rocket Pharmaceuticals compare to Urogen Pharma?

Which has preferable valuation & earnings, RCKT or URGN?

Do institutionals & insiders hold more shares of RCKT or URGN?

Is RCKT or URGN more profitable?

Do analysts rate RCKT or URGN?

Does the media prefer RCKT or URGN?

Which has more risk and volatility, RCKT or URGN?

Summary

How does Rocket Pharmaceuticals compare to Compass Pathways?

Do institutionals & insiders believe in CMPS or RCKT?

Which has more volatility & risk, CMPS or RCKT?

Which has preferable valuation & earnings, CMPS or RCKT?

Do analysts prefer CMPS or RCKT?

Is CMPS or RCKT more profitable?

Does the media prefer CMPS or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Phibro Animal Health?

Does the media favor RCKT or PAHC?

Do analysts recommend RCKT or PAHC?

Which has better valuation & earnings, RCKT or PAHC?

Which has more risk & volatility, RCKT or PAHC?

Do institutionals and insiders believe in RCKT or PAHC?

Is RCKT or PAHC more profitable?

Summary

How does Rocket Pharmaceuticals compare to Bicara Therapeutics?

Which has more risk & volatility, BCAX or RCKT?

Which has preferable valuation and earnings, BCAX or RCKT?

Do institutionals & insiders hold more shares of BCAX or RCKT?

Does the media refer more to BCAX or RCKT?

Is BCAX or RCKT more profitable?

Do analysts prefer BCAX or RCKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools